Caplin Point Laboratories (524742) Q3 24/25 earnings summary

Executive summary

• Nine-month FY25 revenue nearly matches or surpasses FY23 full-year levels, reflecting strong growth momentum and consistent double-digit increases across quarters.

• Expansion in Latin America (Mexico, Chile, Brazil, Colombia) and the U.S., with new product launches, own-label ramp-up, and approvals driving future growth.

• R&D pipeline includes 80-85 APIs, semaglutide tablets, specialty excipients, and biostimulants, with asset-light manufacturing in China and high R&D spend as a percentage of PAT.

• No domestic business in India; all growth is export-driven, with a strategic shift to own-label launches in the U.S. for higher margins.

• Free cash reserves at ₹1,081 Cr and total liquid assets at ₹2,042 Cr as of Dec 31, 2024, supporting ongoing expansion.

Financial highlights

• Q3 FY25 revenue rose 15.8% YoY to ₹524.3 Cr; 9MFY25 revenue up 16.7% YoY to ₹1,505.7 Cr.

• Q3 FY25 EBITDA margin at 36.9%, PAT margin at 26.7%; 9MFY25 PAT at ₹395.8 Cr, up 16.3% YoY.

• US market revenue for 9MFY25 grew 23% YoY to ₹258 Cr; Latin America remains the largest contributor.

• Oncology business turned profitable with ₹34 Cr revenue in 9MFY25.

• Free cash flow of ₹153 Cr in 9MFY25 after capex investment.

Outlook and guidance

• U.S. business expected to remain a primary growth engine for the next 3-5 years, with 10 more ANDA approvals anticipated in the next few quarters.

• Significant revenue from non-U.S. markets anticipated from FY26 as new registrations and manufacturing ramp up, with expansion into regulated markets like Canada, Australia, and Brazil.

• Targeting $100 million sales in Caplin Steriles by FY27-FY28, with 25-30% annual growth considered strong.

• Capex of ₹1,000+ Cr planned, with 50% nearing completion; all funded through internal accruals.

• Margins expected to remain strong and sustainable over the next 2-3 years.